Apogee Therapeutics (APGE) EBITDA (2022 - 2026)

Apogee Therapeutics (APGE) has reported EBITDA for 5 consecutive years, with -$82.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA fell 31.18% year-over-year to -$82.8 million; the TTM figure through Mar 2026 stood at -$305.3 million (down 26.26% YoY), while the FY2025 annual figure was -$285.6 million, down 31.69% from the prior year.
• EBITDA fell to -$82.8 million in Q1 2026 per APGE's latest filing, from -$78.1 million in the prior quarter.
• Across five years, EBITDA topped out at -$1.8 million in Q2 2022 and bottomed at -$82.8 million in Q1 2026.
• Historically, EBITDA has averaged -$44.0 million across 5 years, with a median of -$41.2 million in 2024.
• Annual changes were most pronounced in 2023 — EBITDA plunged 939.92% — and 2025, when it decreased 2.87%.
• Apogee Therapeutics' EBITDA stood at -$14.1 million in 2022, then tumbled by 163.53% to -$37.2 million in 2023, then sank by 104.23% to -$75.9 million in 2024, then fell by 2.87% to -$78.1 million in 2025, then declined by 6.04% to -$82.8 million in 2026.
• Business Quant data shows APGE's EBITDA at -$82.8 million in Q1 2026, -$78.1 million in Q4 2025, and -$71.3 million in Q3 2025.